2025-05-29-Jefferies-恩诺维斯（ENOV）_2025年良好开局_专注于执行_看好2025年及以后；目标价60美元_买入_25页_1mb

报告摘要

Rating and Price Target: Jefferies maintains a "Buy" rating with a $60 price target (+84% upside), based on 11.5x 2026E EV/EBITDA.
Recent Performance: ENOV achieved 8% xfx selling day growth and 10% xfx revenue in Q1 2025, driven by Lima integration, portfolio completion, and commercial execution. EBITDA improved by 160 bps to ~18%, and gross margin reached ~62%.
Market Outlook: Orthopedic and rehabilitation markets are growing due to favorable demographics, innovations, and post-COVID trends. US Recon market is solid/stable through 2025, with OUS growth offsetting minor softness. ENOV focuses on higher-growth Extremities segments, contributing ~50% of Recon exposure.
Valuation: Shares trade at ~7.5x 2026E EV/EBITDA, undervalued compared to SMid-cap peers (mean EV/EBITDA multiple is higher by 2-4 turns), with potential for multiple expansion.
Key Risks: Competition, macroeconomic headwinds, pricing pressure, supply chain disruptions (tariffs impact $20M in 2025E EBITDA), and regulatory challenges (EU MDR).
Strategic Initiatives: Focus on bolt-on M&A, organic growth in high-margin Recon (e.g., Empowr Knee), cross-selling opportunities, and ASC penetration. Plans to delever to <3x debt/EBITDA and improve FCF conversion.
Guidance: Non-GAAP revs for 2025E are $2.22B–$2.25B (5–6% growth), EBITDA $385–$395M (down 5% due to tariffs), with EPS $2.95–$3.10. Adjusted EBITDA margin expands to ~17.5% in 2026E.